Pharma Mar, S.A.
PHMMF
Other OTC106.48
USD
- -
- -
ISIN
ES0169501022
Return %
Stock
S&P500
1Y
2.78
26.53
3Y
212.07
76.60
5Y
8.70
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jose Maria Fernandez Sousa-Faro
- Full Time Employees
- 500
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Avenida de los Reyes, 1 Madrid Spain 28770
- IPO Date
- Feb 23, 2016
- Website
- pharmamar.com
- Similar Companies
- Business
- Pharma Mar, S.A. is a Spain-based integrated biopharmaceutical company specializing in the research, development, production, and commercialization of marine-derived pharmaceutical drugs primarily for oncology. The company’s main products include Yondelis (trabectedin), indicated for advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer, and Zepzelca (lurbinectedin), approved for metastatic small cell lung cancer. Pharma Mar also operates subsidiaries such as Genomica, which focuses on molecular diagnostics including infectious diseases, and Sylentis, which develops RNA interference-based gene silencing therapies. The company’s core business segments encompass Oncology, Diagnostics, and RNA interference, underpinned by a strong R&D pipeline featuring drug candidates like Ecubectedina (PM14), PM54 (a potential second-generation lurbinectedin), and PM534, targeting various solid tumors. Founded in 1986 and headquartered in Madrid, Pharma Mar operates globally with subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria, and the United States. Recent significant developments include Pharma Mar reporting an 11% increase in total revenues to €174.9 million in 2024, driven notably by a 38.5% rise in licensing revenues linked to strategic partnership agreements, including with Jazz Pharmaceuticals. A major milestone was achieved with positive Phase 3 IMforte clinical trial results for a combination therapy of lurbinectedin and atezolizumab in small cell lung cancer, demonstrating clear survival benefits. Pharma Mar plans regulatory submissions for European marketing authorization of lurbinectedin in early 2025, with partner Jazz Pharmaceuticals targeting FDA approval. The company also advanced its sustainability initiatives by publishing a Sustainability Report and adopting human rights, biodiversity, and Net Zero decarbonization policies. Pharma Mar is focusing on expanding its oncology portfolio through ongoing clinical developments and potential in-licensing opportunities to bolster its competitive position in global markets. Pharma Mar’s business model targets oncology patients and healthcare providers worldwide, leveraging marine bioactive compounds to deliver innovative cancer therapies. Its integrated approach combines pharmaceuticals, diagnostics, and gene-silencing technologies to address complex medical needs. The company maintains a robust financial position to support pipeline advancement and strategic corporate growth in the evolving biopharma landscape.
PMV Pharmaceuticals Announces Board Chair Transition
Pharma Mar, S.A. (PHMMF) Q4 2025 Earnings Call Transcript
Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)
Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript